PureTech Health plc PRTC NASDAQ · Healthcare · United States
$17.42 -0.06% -$0.01
Summary
40 / 100 · Bulios Score
What speaks for it
- Revenue grew by 31% a year over the last 3 years.
- It holds more cash than debt: $280.6M against $22.4M.
- It bought back its own shares for $107.6M in the last fiscal year, 25% of its market value.
What to watch
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 11% a year over 5 years. Over the last 3 years it grew by 31% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.